{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:06:40Z","timestamp":1785607600966,"version":"3.56.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The influenza vaccination is known as the most effective method for preventing influenza infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis), MF59-adjuvanted (Fluad; Novartis), and intradermal (IDflu15; Sanofi Pasteur) influenza vaccines are widely used throughout South Korea. However, few comparative studies evaluating the safety and immunogenicity of these vaccines are available. Prior to the beginning of the 2011-2012 influenza season, 335 healthy elderly volunteers randomly received one of three seasonal trivalent influenza vaccines, the conventional subunit, MF59-adjuvanted, or intradermal influenza vaccine. Serum hemagglutination-inhibiting antibody levels were measured at the time of vaccination and at 1 and 6 months after vaccination. Adverse events were recorded prospectively. A total of 113 conventional subunit, 111 MF59-adjuvanted, and 111 intradermal influenza vaccine volunteers were followed up during a 6-month postvaccination period. One month after vaccination, all three vaccines satisfied Committee for Medical Products for Human Use (CHMP) immunogenicity criteria for the A\/H1N1 and A\/H3N2 strains but not for the B strain. Compared with the subunit vaccine, the intradermal vaccine exhibited noninferiority, while the MF59-adjuvanted vaccine exhibited superiority. Furthermore, the MF59-adjuvanted vaccine was more immunogenic against the A\/H3N2 strain than was the subunit vaccine up to 6 months postvaccination. The most common local and systemic reactions to the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines were pain at the injection site (7.1%, 10.8%, and 6.3%, respectively) and generalized myalgia (0.9%, 8.1%, and 5.4%, respectively). Local and systemic reactions were similar among the three vaccine groups. MF59-adjuvanted vaccine exhibited superior immunogenicity compared with a conventional subunit vaccine and had a comparable safety profile. For older adults, the MF59-adjuvanted vaccine is preferable for providing superior immunogenicity.<\/jats:p>","DOI":"10.1128\/cvi.00615-13","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T03:49:38Z","timestamp":1400125778000},"page":"989-996","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["Comparison of the Immunogenicity and Safety of the Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccines in the Elderly"],"prefix":"10.1128","volume":"21","author":[{"given":"Yu Bin","family":"Seo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Suk","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Cheong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Joo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"},{"name":"Transgovernmental Enterprise for Pandemic Influenza in Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.3.265"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/425315"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1333"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis574"},{"key":"e_1_3_2_6_2","first-page":"256","article-title":"The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community","volume":"88","author":"Praditsuwan R","year":"2005","unstructured":"PraditsuwanRAssantachaiPWasiCPuthavatanaPKositanontU. 2005. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J. Med. Assoc. Thai. 88:256\u2013264.","journal-title":"J. Med. Assoc. Thai."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520210045030"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.105"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/529197"},{"key":"e_1_3_2_10_2","first-page":"68","article-title":"Immunosenescence and challenges of vaccination against influenza in the aging population","volume":"3","author":"Reber AJ","year":"2012","unstructured":"ReberAJChirkovaTKimJHCaoWBiberRShayDKSambharaS. 2012. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis. 3:68\u201390.","journal-title":"Aging Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-92165-3_20"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25580"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.064"},{"key":"e_1_3_2_14_2","volume-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"FDA","year":"2010","unstructured":"FDA. 2010. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. FDA, Rockville, MD. http:\/\/www.fda.gov\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/vaccines\/ucm074775.htm."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-134"},{"key":"e_1_3_2_16_2","volume-title":"Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines","author":"Center for Biologics Evaluation and Research, FDA","year":"2010","unstructured":"Center for Biologics Evaluation and Research, FDA. 2010. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3204-z"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4933-5-2"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05726-11"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.10.007"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.033"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/590434"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.077"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00138-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017919305501"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00185-6"},{"key":"e_1_3_2_27_2","first-page":"121","article-title":"Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity","volume":"50","author":"Sindoni D","year":"2009","unstructured":"SindoniDLa FauciVSqueriRCannavoGBacilieriSPanattoDGaspariniRAmiciziaD. 2009. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J. Prev. Med. Hyg. 50:121\u2013126.","journal-title":"J. Prev. Med. Hyg."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00499-0"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00615-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00615-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:00Z","timestamp":1627591860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00615-13"}},"subtitle":[],"editor":[{"given":"S. A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1128\/CVI.00615-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00615-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"2013-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}